SG3 Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

SG3 Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,900	Closed	-$344K	–	1000
2022 Q1	$344K	Buy	+2,900	New	+$362K	0.01%	675
2021 Q3	–	Sell	-24,000	Closed	-$2.33M	–	1379
2021 Q2	$2.33M	Buy	24,000 +17,000	+243%	+$1.38M	0.08%	280
2021 Q1	$478K	Buy	7,000 +3,000	+75%	+$243K	0.01%	788
2020 Q4	$343K	Sell	4,000 -38,925	-91%	-$3.3M	0.01%	793
2020 Q3	$2.79M	Buy	+42,925	New	+$2.81M	0.1%	218

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SG3 Management's BHVN Position: Q2 2022 in Review

SG3 Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 2,900 shares — an estimated $344K sold.

SG3 Management first reported a position in BHVN in Q3 2020 and held it in 5 quarters. The position peaked at $2.79M in Q3 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

SG3 Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 2,900 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $344K.
SG3 Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2020 and held it in 5 quarters.
SG3 Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.79M in Q3 2020.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.